Condition: Adenocarcinoma of Lung · Carcinoma, Non-Small-Cell Lung · Sponsor: Lantern Pharma Inc.
The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined patient population when LP-300 is co-administered with the standard of care chemotherapy drugs carboplatin and pemetrexed compared to carboplatin and pemetrexed alone. This has been designed as a multicenter, open label, phase II trial with 90 patients to be enrolled in the United States.
This description comes directly from the study's public registry record.
Sandra Sinclair · 832.622.1699 · sandra@lanternpharma.com
Always discuss trial participation with your own doctor first.
| Precision NextGen Oncology and Research Center | Beverly Hills, California, United States | Recruiting |
| Los Angeles Cancer Network | Fountain Valley, California, United States | Recruiting |
| Cancer and Blood Specialists Clinic | Los Alamitos, California, United States | Suspended |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| UT Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| Inova Fairfax Hospital | Fairfax, Virginia, United States | Recruiting |
| Hokkaido Cancer Center | Sapporo, Hokkaido, Japan | Active Not Recruiting |
| Kanagawa Cancer Center Hospital | Yokohama, Kanagawa, Japan | Active Not Recruiting |
| Tohoku University Hospital | Sendai, Miyagi, Japan | Active Not Recruiting |
| Okayama University Hospital | Okayama, Okayama-ken, Japan | Active Not Recruiting |
| National Cancer Center Hospital | Chuo-ku, Tokyo, Japan | Active Not Recruiting |
| National Taiwan University Hospital Hsin-Chu Branch | Hsinchu, Taiwan | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05456256